S&P 500   2,997.95 (+0.28%)
DOW   27,025.88 (+0.09%)
QQQ   193.41 (+0.19%)
AAPL   234.33 (-0.02%)
FB   189.67 (+0.06%)
MSFT   139.47 (-0.67%)
GOOGL   1,253.85 (+0.87%)
AMZN   1,790.38 (+0.73%)
CGC   20.31 (+2.94%)
NVDA   192.60 (-0.83%)
MU   45.44 (+0.62%)
BABA   176.24 (-0.50%)
GE   9.07 (+1.80%)
TSLA   262.42 (+1.03%)
AMD   31.02 (+0.68%)
T   37.78 (-0.03%)
F   9.10 (+0.33%)
ACB   3.80 (+5.27%)
PRI   123.96 (+0.07%)
NFLX   293.35 (+2.47%)
BAC   30.07 (-0.33%)
GILD   65.16 (-0.29%)
DIS   132.86 (+1.53%)
S&P 500   2,997.95 (+0.28%)
DOW   27,025.88 (+0.09%)
QQQ   193.41 (+0.19%)
AAPL   234.33 (-0.02%)
FB   189.67 (+0.06%)
MSFT   139.47 (-0.67%)
GOOGL   1,253.85 (+0.87%)
AMZN   1,790.38 (+0.73%)
CGC   20.31 (+2.94%)
NVDA   192.60 (-0.83%)
MU   45.44 (+0.62%)
BABA   176.24 (-0.50%)
GE   9.07 (+1.80%)
TSLA   262.42 (+1.03%)
AMD   31.02 (+0.68%)
T   37.78 (-0.03%)
F   9.10 (+0.33%)
ACB   3.80 (+5.27%)
PRI   123.96 (+0.07%)
NFLX   293.35 (+2.47%)
BAC   30.07 (-0.33%)
GILD   65.16 (-0.29%)
DIS   132.86 (+1.53%)
Log in

Proteome Sciences Stock Price, News & Analysis (LON:PRM)

GBX 2.74
-0.01 (-0.36 %)
(As of 10/17/2019 04:00 PM ET)
Today's Range
2.74
Now: GBX 2.74
2.74
50-Day Range
2.65
MA: GBX 3.10
3.55
52-Week Range
2.20
Now: GBX 2.74
4.30
VolumeN/A
Average Volume88,695 shs
Market Capitalization£8.09 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers. It delivers content for personalized medicine in the areas of biomarker services, isobaric reagents, and biomarkers. The company designs, performs, and interprets high resolution proteomics studies to improve target discovery, validation, and mechanism of action studies; offers specialized services to enhance discovery and validation of mechanistic biomarkers in peripheral fluids; and provides a set of bioinformatics tools to enhance data integration, and select regulated features and map to biological processes. Read More…

Industry, Sector and Symbol

Industry Medical Laboratories & Research
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-20-70432116

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales£3.47 million
Cash FlowGBX 0.30 per share
Book ValueGBX (1.40) per share

Profitability

Miscellaneous

Employees29
Market Cap£8.09 million
Next Earnings DateN/A
OptionableNot Optionable

Receive PRM News and Ratings via Email

Sign-up to receive the latest news and ratings for PRM and its competitors with MarketBeat's FREE daily newsletter.


Proteome Sciences (LON:PRM) Frequently Asked Questions

What is Proteome Sciences' stock symbol?

Proteome Sciences trades on the London Stock Exchange (LON) under the ticker symbol "PRM."

Has Proteome Sciences been receiving favorable news coverage?

Media headlines about PRM stock have trended somewhat negative recently, according to InfoTrie. The research firm identifies negative and positive press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Proteome Sciences earned a media sentiment score of -1.9 on InfoTrie's scale. They also gave headlines about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for Proteome Sciences.

Who are some of Proteome Sciences' key competitors?

Some companies that are related to Proteome Sciences include VolitionRX (VNRX), ANGLE (AGL), Spectral Medical (EDT), DiaSorin (DIA), Polarityte (COOL) and Premaitha Health (NIPT).

What other stocks do shareholders of Proteome Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Proteome Sciences investors own include ValiRx (VAL), Mondi (MNDI), Petrofac (PFC), Boohoo Group (BOO), Falanx Group (FLX), Lloyds Banking Group (LLOY), Quanterix (QTRX), Cyanconnode (CYAN), Eckoh (ECK) and IQE (IQE).

Who are Proteome Sciences' key executives?

Proteome Sciences' management team includes the folowing people:
  • Dr. Jeremy Rupert Michael Haigh, CEO & Exec. Director (Age 58)
  • Dr. Ian H. Pike, Chief Scientific Officer & Exec. Director
  • Mr. Richard Paul Dennis, Chief Commercial Officer & Exec. Director (Age 60)
  • Mr. Stefan Fuhrmann, Interim Fin. Director
  • Dr. Josef Schwarz, Chief Compliance Officer

How do I buy shares of Proteome Sciences?

Shares of PRM and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Proteome Sciences' stock price today?

One share of PRM stock can currently be purchased for approximately GBX 2.74.

How big of a company is Proteome Sciences?

Proteome Sciences has a market capitalization of £8.09 million and generates £3.47 million in revenue each year. Proteome Sciences employs 29 workers across the globe.View Additional Information About Proteome Sciences.

What is Proteome Sciences' official website?

The official website for Proteome Sciences is http://www.proteomics.com/.

How can I contact Proteome Sciences?

Proteome Sciences' mailing address is Hamilton House, Mabledon Place, LONDON, WC1H 9BB, United Kingdom. The company can be reached via phone at +44-20-70432116.


MarketBeat Community Rating for Proteome Sciences (LON PRM)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  141 (Vote Outperform)
Underperform Votes:  215 (Vote Underperform)
Total Votes:  356
MarketBeat's community ratings are surveys of what our community members think about Proteome Sciences and other stocks. Vote "Outperform" if you believe PRM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/17/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel